582 related articles for article (PubMed ID: 30113926)
1. Analysis of survival and prognostic factors in treatment of hepatocellular carcinoma in Spanish patients with drug-eluting bead transarterial chemoembolization.
Sánchez-Delgado J; Vergara M; Machlab S; Lira A; Gómez Zaragoza C; Criado E; Rosinach M; Batista L; Arau B; Roget M; Ortiz J; Garcia C; Sort P; Casas M; Dalmau B; Forné M; Falcó J; Miquel M
Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1453-1460. PubMed ID: 30113926
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of doxorubicin drug-eluting bead transarterial chemoembolization in patients with advanced hepatocellular carcinoma.
Prajapati HJ; Dhanasekaran R; El-Rayes BF; Kauh JS; Maithel SK; Chen Z; Kim HS
J Vasc Interv Radiol; 2013 Mar; 24(3):307-15. PubMed ID: 23375519
[TBL] [Abstract][Full Text] [Related]
3. The ART-SCORE is not an effective tool for optimizing patient selection for DEB-TACE retreatment. A multicentre Spanish study.
Pipa-Muñiz M; Castells L; Pascual S; Fernández-Castroagudín J; Díez-Miranda I; Irurzun J; Díaz-Beveridge R; Senosiaín M; Arenas J; de la Mata M; Turnes J; Monge-Romero MI; Pérez-Enguix D; Bustamante-Schneider J; Otegui N; Molina-Pérez E; Rodríguez-Menéndez JE; Varela M
Gastroenterol Hepatol; 2017 Oct; 40(8):515-524. PubMed ID: 28676199
[TBL] [Abstract][Full Text] [Related]
4. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
5. Safety and effectiveness of chemoembolization with drug-eluting beads for advanced-stage hepatocellular carcinoma.
Kalva SP; Pectasides M; Liu R; Rachamreddy N; Surakanti S; Yeddula K; Ganguli S; Wicky S; Blaszkowsky LS; Zhu AX
Cardiovasc Intervent Radiol; 2014 Apr; 37(2):381-7. PubMed ID: 23754191
[TBL] [Abstract][Full Text] [Related]
6. Survival, efficacy, and safety of small versus large doxorubicin drug-eluting beads TACE chemoembolization in patients with unresectable HCC.
Prajapati HJ; Xing M; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
AJR Am J Roentgenol; 2014 Dec; 203(6):W706-14. PubMed ID: 25415737
[TBL] [Abstract][Full Text] [Related]
7. [Comparison of doxorubicin-eluting bead transarterial chemoembolization (DEB-TACE) with conventional transarterial chemoembolization (TACE) for the treatment of hepatocellular carcinoma].
Ferrer Puchol MD; la Parra C; Esteban E; Vaño M; Forment M; Vera A; Cosín O
Radiologia; 2011; 53(3):246-53. PubMed ID: 21295802
[TBL] [Abstract][Full Text] [Related]
8. Transcatheter arterial chemoembolization with doxorubicin-eluting superabsorbent polymer microspheres in the treatment of hepatocellular carcinoma: midterm follow-up.
Dekervel J; van Malenstein H; Vandecaveye V; Nevens F; van Pelt J; Heye S; Laleman W; Van Steenbergen W; Vaninbroukx J; Verslype C; Maleux G
J Vasc Interv Radiol; 2014 Feb; 25(2):248-55.e1. PubMed ID: 24295569
[TBL] [Abstract][Full Text] [Related]
9. Imaging Changes and Clinical Complications After Drug-Eluting Bead Versus Conventional Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma: Multicenter Study.
Zhang L; Sun JH; Ji JS; Zhong BY; Zhou GH; Song JJ; Hou ZH; Huang P; Zhang S; Li Z; Zhu XL; Ni CF
AJR Am J Roentgenol; 2021 Oct; 217(4):933-943. PubMed ID: 33245680
[No Abstract] [Full Text] [Related]
10. Conventional Versus Small Doxorubicin-eluting Bead Transcatheter Arterial Chemoembolization for Treating Barcelona Clinic Liver Cancer Stage 0/A Hepatocellular Carcinoma.
Kang YJ; Lee BC; Kim JK; Yim NY; Kim HO; Cho SB; Jeong YY
Cardiovasc Intervent Radiol; 2020 Jan; 43(1):55-64. PubMed ID: 31646378
[TBL] [Abstract][Full Text] [Related]
11. Five-year outcome of conventional and drug-eluting transcatheter arterial chemoembolization in patients with hepatocellular carcinoma.
Liu YS; Lin CY; Chuang MT; Lin CY; Tsai YS; Wang CK; Ou MC
BMC Gastroenterol; 2018 Aug; 18(1):124. PubMed ID: 30075752
[TBL] [Abstract][Full Text] [Related]
12. Survival, tumour response and safety of 70-150 μm versus 100-300 μm doxorubicin drug-eluting beads in transarterial chemoembolisation for hepatocellular carcinoma.
Huo YR; Xiang H; Chan MV; Chan C
J Med Imaging Radiat Oncol; 2019 Dec; 63(6):802-811. PubMed ID: 31709778
[TBL] [Abstract][Full Text] [Related]
13. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study.
Dhanasekaran R; Kooby DA; Staley CA; Kauh JS; Khanna V; Kim HS
HPB (Oxford); 2010 Apr; 12(3):174-80. PubMed ID: 20590884
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
15. Hepatic arterial damage after transarterial chemoembolization for the treatment of hepatocellular carcinoma: comparison of drug-eluting bead and conventional chemoembolization in a retrospective controlled study.
Lee S; Kim KM; Lee SJ; Lee KH; Lee DY; Kim MD; Kim DY; Kim SU; Won JY
Acta Radiol; 2017 Feb; 58(2):131-139. PubMed ID: 27217418
[TBL] [Abstract][Full Text] [Related]
16. Comparison of lipiodol infusion and drug-eluting beads transarterial chemoembolization of hepatocellular carcinoma in a real-life setting.
Karalli A; Teiler J; Haji M; Seth E; Brismar TB; Wahlin S; Axelsson R; Stål P
Scand J Gastroenterol; 2019 Jul; 54(7):905-912. PubMed ID: 31287338
[No Abstract] [Full Text] [Related]
17. Open-Label Single-Arm Phase II Trial of Sorafenib Therapy with Drug-eluting Bead Transarterial Chemoembolization in Patients with Unresectable Hepatocellular Carcinoma: Clinical Results.
Cosgrove DP; Reyes DK; Pawlik TM; Feng AL; Kamel IR; Geschwind JF
Radiology; 2015 Nov; 277(2):594-603. PubMed ID: 26069923
[TBL] [Abstract][Full Text] [Related]
18. Conventional versus drug-eluting beads chemoembolization for infiltrative hepatocellular carcinoma: a comparison of efficacy and safety.
Zhang ZS; Li HZ; Ma C; Xiao YD
BMC Cancer; 2019 Nov; 19(1):1162. PubMed ID: 31783814
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin-loaded drug-eluting beads versus conventional transarterial chemoembolization for nonresectable hepatocellular carcinoma.
Arabi M; BenMousa A; Bzeizi K; Garad F; Ahmed I; Al-Otaibi M
Saudi J Gastroenterol; 2015; 21(3):175-80. PubMed ID: 26021777
[TBL] [Abstract][Full Text] [Related]
20. Short-term efficacy and safety of callispheres drug-loaded microsphere embolization in primary hepatocellular carcinoma.
Li J; Wang N; Shi C; Liu Q; Song J; Ye X
J Cancer Res Ther; 2021 Jul; 17(3):733-739. PubMed ID: 34269307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
